Mental Health Trends Among US Youths: Rising Prevalence of Depression and Anxiety

By Danélia Botes

October 7, 2024

Introduction

Mental health disorders, particularly depression and anxiety, significantly impact US children and adolescents. With an annual cost of $247 billion, these conditions affect millions and pose a substantial burden on society. Recent data highlights an increase in clinically diagnosed depression and anxiety among youths aged 5 to 22 years from 2017 to 2021. These trends are drawn from a large integrated healthcare system in Southern California. A recent analysis focuses on the incidence and prevalence of these disorders, considering factors such as age, gender, race, ethnicity, and weight status.

Rising Incidence and Prevalence

The period from 2017 to 2021 saw a marked increase in clinically diagnosed depression and anxiety among youths. Depression incidence rose by 55.6%, while prevalence increased by 60.0%. Anxiety without depression also showed significant growth, with a 31.1% rise in incidence and a 35.2% increase in prevalence. These trends were more pronounced during the COVID-19 pandemic, reflecting heightened mental health challenges during this period. Adolescents aged 14 to 17 and young adults aged 18 to 22 experienced the highest rates of depression. Anxiety without depression was notably higher among underweight individuals.

Figure 1. Prevalence of Clinically Diagnosed Depression per 100 Participants From 2017 to 2021

Demographic Disparities

The study reveals significant disparities in mental health diagnoses across various demographic groups. Female youths, those of American Indian, Alaska Native, or non-Hispanic White descent, and individuals from higher-income households exhibited higher rates of depression. Anxiety without depression was more prevalent among underweight individuals. These findings align with previous research indicating higher depression and anxiety rates among girls, older children, and those of White ethnicity. Interestingly, the study found higher depression and anxiety rates among youths from affluent families, contrasting with earlier survey data.

Impact of Weight Status

Weight status emerged as a critical factor influencing anxiety without depression. Underweight individuals exhibited the highest incidence and prevalence rates. Previous studies suggest that weight-related teasing may contribute to social isolation and mental health issues among underweight youths. Findings emphasise the need for early interventions to address anxiety in this group, potentially preventing the onset of depression. Obesity, a known risk factor for depression, further complicates the mental health landscape for affected youths.

 

COVID-19 Pandemic Influence

The COVID-19 pandemic significantly disrupted healthcare systems and exacerbated mental health challenges for adolescents. The data indicate that the pandemic contributed to the rising trends in depression and anxiety diagnoses. Despite healthcare access challenges, the rates of newly diagnosed clinical depression did not decline during 2020. Instead, the pandemic intensified existing trends, with 2021 recording the highest incidence of depression and anxiety without depression. This highlights the need for robust mental health services to support youths during and beyond the pandemic.

Conclusion

This recent study highlights the increasing incidence and prevalence of clinically diagnosed depression and anxiety without depression among US youths. These trends, observed across all demographic groups, call for enhanced mental health services. Addressing disparities in mental health diagnoses and providing early interventions for at-risk groups, such as underweight individuals, are crucial steps toward improving the well-being of our young population. As we navigate the post-pandemic landscape, strengthening mental health support systems remains imperative.

Reference url

Recent Posts

Global AIDS Update 2024
     

Global AIDS Update 2024: Progress and Challenges

📊 The **2024 Global AIDS Update** from UNAIDS reveals critical insights on the ongoing HIV epidemic, progress made, and the challenges that lie ahead.

With nearly 40 million people living with HIV worldwide, it’s clear that while we are progressing, much work remains to ensure equitable access to treatment and services. Learn more about the current trends, treatment coverage, and the urgent need for a sustainable response that respects health and human rights.

#SyenzaNews #HIVAIDS #GlobalHealth

obesity early prevention
       

Early Prevention of Obesity: Tackling from Conception

🔍 Discover groundbreaking insights on obesity prevention from the womb! The insight discusses the importance of monitoring and intervening early to combat obesity through the eprObes project. This proactive approach emphasises the critical role of prenatal care and aims to improve health outcomes for future generations.

Read more to find out how addressing obesity from conception can change lives!

#SyenzaNews #ObesityPrevention #PrenatalCare

inavolisib breast cancer treatment
        

FDA Approves Inavolisib Breast Cancer Treatment

🌟 Big news in breast cancer treatment! The FDA has approved inavolisib (Itovebi) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer. This innovative therapy offers new hope for patients who have faced recurrence after prior endocrine therapy.

Learn more about the significant trial outcomes and the role of the FoundationOne Liquid CDx companion diagnostic!

#SyenzaNews #BreastCancer #FDAApproval

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.